Rasburicase

Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout[1][2][3].

Product Specifications

CAS Number

[134774-45-1]

UNSPSC

12352211

Hazard Statement

H317, H334

Target

Xanthine Oxidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/rasburicase.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Rasburicase]

Precautions

H317, H334

References & Citations

[1]Cammalleri L, et al. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci. 2007 Mar 2;4 (2) :83-93.|[2]Xu H, et al. High-Dose IV Administration of Rasburicase Suppresses Anti-rasburicase Antibodies, Depletes Rasburicase-Specific Lymphocytes, and Upregulates Treg Cells. AAPS J. 2020 May 27;22 (4) :80.|[3]Kono H, et al. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest. 2010 Jun;120 (6) :1939-49.